Aristolochic acid I (AAI) is a plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa). We previously investigated the efficiencies of human and rat CYPs in the presence of two other components of the mixed-functions-oxidase system, NADPH:CYP oxidoreductase and cytochrome b₅, to oxidize AAI. Human and rat CYP1A are the major enzymes oxidizing AAI. Other CYPs such as CYP2C, 3A4, 2D6, 2E1, and 1B1, also form AAIa, but with much lower efficiency than CYP1A. Based on velocities of AAIa formation by examined CYPs and their expression levels in human and rat livers, here we determined the contributions of individual CYPs to AAI oxidation in these organs. Human CYP1A2 followed by CYP2C9, 3A4 and 1A1 were the major enzymes contributing to AAI oxidation in human liver, while CYP2C and 1A were most important in rat liver. We employed flexible in silico docking methods to explain the differences in AAI oxidation in the liver by human CYP1A1, 1A2, 2C9, and 3A4, the enzymes that all O-demethylate AAI, but with different effectiveness. We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation. Our results indicate that utilization of experimental and theoretical methods is an appropriate study design to examine the CYP-catalyzed reaction mechanisms of AAI oxidation and contributions of human hepatic CYPs to this metabolism.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Albertov 2030 Prague 2 CZ 12843 Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Im Neuenheimer Feld 280 Heidelberg 69120 Germany

000      

00000naa a2200000 a 4500

001      

bmc16027930

003      

CZ-PrNML

005      

20171215201519.0

007      

ta

008      

161005s2015 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/ijms161126047 $2 doi

024    7_

$a 10.3390/ijms161126047 $2 doi

035    __

$a (PubMed)26593908

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, Prague 2 CZ-12843, Czech Republic. stiborov@natur.cuni.cz.

245    12

$a A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches / $c M. Stiborová, F. Bárta, K. Levová, P. Hodek, HH. Schmeiser, VM. Arlt, V. Martínek,

520    9_

$a Aristolochic acid I (AAI) is a plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. AAI is detoxified by cytochrome P450 (CYP)-mediated O-demethylation to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa). We previously investigated the efficiencies of human and rat CYPs in the presence of two other components of the mixed-functions-oxidase system, NADPH:CYP oxidoreductase and cytochrome b₅, to oxidize AAI. Human and rat CYP1A are the major enzymes oxidizing AAI. Other CYPs such as CYP2C, 3A4, 2D6, 2E1, and 1B1, also form AAIa, but with much lower efficiency than CYP1A. Based on velocities of AAIa formation by examined CYPs and their expression levels in human and rat livers, here we determined the contributions of individual CYPs to AAI oxidation in these organs. Human CYP1A2 followed by CYP2C9, 3A4 and 1A1 were the major enzymes contributing to AAI oxidation in human liver, while CYP2C and 1A were most important in rat liver. We employed flexible in silico docking methods to explain the differences in AAI oxidation in the liver by human CYP1A1, 1A2, 2C9, and 3A4, the enzymes that all O-demethylate AAI, but with different effectiveness. We found that the binding orientations of the methoxy group of AAI in binding centers of the CYP enzymes and the energies of AAI binding to the CYP active sites dictate the efficiency of AAI oxidation. Our results indicate that utilization of experimental and theoretical methods is an appropriate study design to examine the CYP-catalyzed reaction mechanisms of AAI oxidation and contributions of human hepatic CYPs to this metabolism.

650    _2

$a metabolická aktivace $7 D065767

650    _2

$a zvířata $7 D000818

650    _2

$a kyseliny aristolochové $x škodlivé účinky $x chemie $x metabolismus $7 D034341

650    _2

$a katalýza $7 D002384

650    _2

$a katalytická doména $7 D020134

650    _2

$a inhibitory cytochromu P450 $x farmakologie $7 D065607

650    _2

$a systém (enzymů) cytochromů P-450 $x chemie $x metabolismus $7 D003577

650    _2

$a lidé $7 D006801

650    _2

$a metabolická inaktivace $7 D008658

650    _2

$a nemoci ledvin $x etiologie $x metabolismus $7 D007674

650    _2

$a játra $x účinky léků $x metabolismus $7 D008099

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a metylace $x účinky léků $7 D008745

650    _2

$a jaterní mikrozomy $x účinky léků $x metabolismus $7 D008862

650    _2

$a molekulární modely $7 D008958

650    _2

$a molekulární konformace $7 D008968

650    _2

$a oxidace-redukce $x účinky léků $7 D010084

650    _2

$a vazba proteinů $7 D011485

650    _2

$a krysa rodu Rattus $7 D051381

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Bárta, František $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, Prague 2 CZ-12843, Czech Republic. frantisek.barta@natur.cuni.cz.

700    1_

$a Levová, Kateřina $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, Prague 2 CZ-12843, Czech Republic. katerina.levova@natur.cuni.cz.

700    1_

$a Hodek, Petr $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, Prague 2 CZ-12843, Czech Republic. hodek@natur.cuni.cz.

700    1_

$a Schmeiser, Heinz H $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany. h.schmeiser@dkfz-heidelberg.de.

700    1_

$a Arlt, Volker M. $u Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment and Health, King's College London, London SE1 9NH, UK. volker.arlt@kcl.ac.uk. $7 xx0074763 $4

700    1_

$a Martínek, Václav $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, Prague 2 CZ-12843, Czech Republic. vacmar@natur.cuni.cz.

773    0_

$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 16, č. 11 (2015), s. 27561-75

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26593908 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20161005 $b ABA008

991    __

$a 20161024110841 $b ABA008

999    __

$a ok $b bmc $g 1166244 $s 952560

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 16 $c 11 $d 27561-75 $e 20151118 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142

LZP    __

$a Pubmed-20161005